Peptides have become one of the most talked-about categories in men's health in 2026 — promoted at longevity clinics, biohacking podcasts, gym communities, and increasingly within sexual medicine itself. Some of the claims are grounded in published clinical research. Many are not. A serious consultation conversation today often includes a patient asking whether PT-141 or BPC-157 might help where Viagra didn't. The honest answer requires separating what's known, what's plausible, and what's marketing.
From Dr. Robbins' PracticeI treat the peptide conversation seriously because patients are spending real money — sometimes thousands of dollars a month — on these products. Some of those dollars are well spent. Many are not. My job is to help patients understand the difference based on the actual published data, not the marketing they encountered on Instagram or in a podcast.
What Peptides Actually Are
A peptide is a short chain of amino acids — smaller than a protein, larger than a single amino acid. Peptides occur naturally in the human body as signaling molecules and have been used in medicine for decades (insulin is a peptide). What's new in the 2026 conversation isn't peptides themselves — it's the boom in synthesized research peptides being marketed as wellness or anti-aging therapies, often outside the FDA-approved drug system.
This regulatory distinction matters. An FDA-approved peptide has gone through formal clinical trials, has approved dosing, has known safety data, and is prescribed for specific indications. A "research peptide" sold by a compounding pharmacy or online vendor has not necessarily done any of these things — even if the molecule itself was originally developed in academic research.
PT-141 (Bremelanotide): The One with Real Evidence
What It Is
PT-141, also called Bremelanotide, is a melanocortin receptor agonist. It works on the central nervous system — in the brain — rather than on blood vessels, which is the mechanism for PDE5 inhibitors like Viagra. By activating melanocortin pathways, PT-141 appears to influence sexual desire and arousal at the level where they originate, not just the downstream vascular response.
PT-141 is FDA-approved (as Vyleesi) for premenopausal women with hypoactive sexual desire disorder. Its use in men is off-label but well-studied; clinical trials in men with erectile dysfunction date back to the early 2000s.
What the Evidence Shows
In men with ED that doesn't fully respond to PDE5 inhibitors, PT-141 has demonstrated efficacy in published studies — particularly when the issue is partly desire-related rather than purely vascular. Men with psychogenic components, low libido alongside ED, or partial response to Viagra/Cialis are the population where PT-141 may add real value.
It is not a substitute for treating the underlying cause of severe vascular ED — men with significant atherosclerosis or post-prostatectomy nerve injury are unlikely to see meaningful benefit. It is also not effective in men whose primary issue is psychological stress without a desire component.
Side Effects and Practical Realities
PT-141 has a real and well-documented side effect profile: nausea (sometimes significant), flushing, transient blood pressure changes, and occasionally headaches. The medication is administered as a subcutaneous injection, not a pill, which itself is a meaningful patient-acceptance hurdle. Effects typically begin within 30–60 minutes and last several hours.
Bottom Line on PT-141
A legitimate option for selected patients, ideally prescribed and monitored through a physician who understands the indication, dosing, and contraindications. Not a first-line therapy. Not for everyone. The clinical literature behind it is real but limited in scope, and the side effect burden is non-trivial.
BPC-157: The One With Almost No Human Evidence
What It Is
BPC-157 (Body Protection Compound 157) is a synthetic peptide fragment derived from a protein found in stomach acid. In animal studies, it has shown remarkable tissue-healing properties — faster recovery from tendon injuries, ulcers, and various inflammatory conditions in rats and other animal models.
What the Evidence Shows
In animals, the data is consistent and impressive. In humans, the data is essentially nonexistent. There are no large-scale, peer-reviewed clinical trials of BPC-157 in humans for any indication, including sexual health. Marketing of BPC-157 for ED, libido, recovery from urological procedures, or sexual performance is based on extrapolation from rodent studies and anecdotal user reports, not clinical evidence.
The FDA has issued warnings about BPC-157, including a 2023 reclassification limiting its compounding for human use. It is not approved for any human indication.
Bottom Line on BPC-157
Promising in animal models. Not validated in humans. Sold widely by compounding pharmacies and online vendors with marketing that significantly outpaces the evidence. I do not recommend BPC-157 to patients for sexual health applications because there is no clinical basis for doing so.
Other Peptides You'll See Marketed
Kisspeptin
Kisspeptin is a real signaling peptide involved in upstream regulation of testosterone production. Clinical research is ongoing for its potential role in male sexual function. As of 2026, it remains primarily a research compound; commercial availability is limited and the clinical evidence is preliminary.
GHK-Cu (Copper Peptide)
A skin and wound-healing peptide with legitimate use in dermatology. Claims about sexual function are not supported by clinical evidence.
"Growth Hormone Secretagogues" (CJC-1295, Ipamorelin, Tesamorelin, etc.)
These peptides aim to increase growth hormone release. Some — like Tesamorelin — are FDA-approved for specific indications (HIV-associated lipodystrophy). Marketing for general anti-aging, libido, or sexual performance applications is largely off-label and lacks robust supporting evidence in healthy men. There are also real safety concerns about long-term GH elevation in adults.
How to Evaluate a Peptide Claim
A practical framework for any peptide pitch:
Is it FDA-approved for the use being marketed? If yes, the answer is well-defined. If no, you are in off-label or research territory, and the burden of evidence is on the prescribing party.
Are there published human clinical trials for this specific use? Not animal studies. Not testimonials. Actual human trials in peer-reviewed journals. Many marketed peptides fail this test.
Is it being prescribed through a clinical workup or shipped from a website without any evaluation? The second pattern should raise serious questions about both safety and source quality.
What is the source? Compounding pharmacies vary widely in quality and oversight. Research peptides sold for "laboratory use only" are exactly that — not validated for human consumption.
Where Peptides Fit in a Real Sexual Medicine Practice
In my practice, peptides are one tool among many — not the default and not the centerpiece. For most men with sexual concerns, the evidence-based foundation is still: lifestyle assessment, cardiovascular and metabolic workup, hormone evaluation (including testosterone if indicated), targeted treatments like shockwave therapy, PRP, or exosome therapy for regenerative goals, and PDE5 inhibitors when appropriate.
PT-141 may be added to that framework for specific patients. The rest of the peptide marketplace warrants skepticism until the evidence catches up to the marketing — which it may or may not, depending on which compound we're discussing.
The Bottom Line
Peptide therapy is not a fad — some peptides have real therapeutic utility — but the gap between what's been validated and what's being sold is wide. A trustworthy sexual medicine consultation in 2026 should be able to discuss peptides without dismissing them and without overselling them. If the conversation is one-sided in either direction, that's a signal worth noting.
At INTIMÉ Miami, Dr. David Robbins offers evidence-based sexual medicine evaluations grounded in current clinical research. Schedule a confidential consultation to discuss what's actually likely to help your specific situation.
Written by Dr. David Robbins — Board-Certified Urologist and Medical Director of INTIMÉ Miami.